Management of invasive group A streptococcal infections

被引:40
|
作者
Waddington, Claire S. [1 ,2 ]
Snelling, Thomas L. [1 ,2 ]
Carapetis, Jonathan R. [1 ,2 ]
机构
[1] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Perth, WA 6872, Australia
[2] Princess Margaret Hosp, Perth, WA 6008, Australia
关键词
Group A streptococcus; Invasive disease; Paediatric; Streptococcal toxic shock syndrome; Necrotising fasciitis; TOXIC-SHOCK-SYNDROME; INTRAVENOUS IMMUNOGLOBULIN THERAPY; EMM-TYPE; SUPERANTIGENIC ACTIVITY; EPIDEMIOLOGIC FEATURES; UNITED-STATES; M-PROTEIN; DISEASE; PYOGENES; CLINDAMYCIN;
D O I
10.1016/j.jinf.2014.08.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Invasive group A streptococcal (GAS) disease in children includes deep soft tissue infection, bacteraemia, bacteraemic pneumonia, meningitis and osteomyelitis. The expression of toxins and super antigens by GAS can complicate infection by triggering an overwhelming systemic inflammatory response, referred to as streptococcal toxic shock syndrome (STSS). The onset and progression of GAS disease can be rapid, and the associated mortality high. Prompt antibiotics therapy and early surgical debridement of infected tissue are essential. Adjunctive therapy with intravenous immunoglobulin and hyperbaric therapy may improve outcomes in severe disease. Nosocomial outbreaks and secondary cases in close personal contacts are not uncommon; infection control measures and consideration of prophylactic antibiotics to those at high risk are important aspects of disease control. To reduce a substantial part of the global burden of GAS disease, an affordable GAS vaccine with efficacy against a broad number of strains is needed. Crown Copyright (C) 2014 Published by Elsevier Ltd on behalf of The British Infection Association. All rights reserved.
引用
收藏
页码:S63 / S69
页数:7
相关论文
共 50 条
  • [31] Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome
    Eriksson, BKG
    Andersson, J
    Holm, SE
    Norgren, M
    CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) : 1428 - 1436
  • [32] Invasive Group A Streptococcal Disease Epidemiology, Pathogenesis and Management
    Steer, Andrew C.
    Lamagni, Theresa
    Curtis, Nigel
    Carapetis, Jonathan R.
    DRUGS, 2012, 72 (09) : 1213 - 1227
  • [33] Invasive group a streptococcal disease: Epidemiology, pathogenesis and management
    Steer A.C.
    Lamagni T.
    Curtis N.
    Carapetis J.R.
    Drugs, 2012, 72 (9) : 1213 - 1227
  • [34] Invasive group A streptococcal infection : management and chemoprophylaxis.
    Allen, U. D.
    Moore, D. L.
    PAEDIATRICS & CHILD HEALTH, 2010, 15 (05) : 299 - 302
  • [35] ICU Management of Invasive b-Hemolytic Streptococcal Infections
    Babiker, Ahmed
    Kadri, Sameer S.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2022, 36 (04) : 861 - 887
  • [36] Group A Streptococcal Infections
    Langlois, Debra M.
    Andreae, Margie
    PEDIATRICS IN REVIEW, 2011, 32 (10) : 423 - 430
  • [37] Group A streptococcal infections
    Jaggi, P
    Shulman, ST
    PEDIATRICS IN REVIEW, 2006, 27 (03) : 99 - 105
  • [38] Gastrointestinal symptomatology as a predictor of severe outcomes of invasive group A streptococcal infections
    Khateeb, O. M.
    Osborne, D.
    Mulla, Z. D.
    EPIDEMIOLOGY AND INFECTION, 2010, 138 (04): : 534 - 541
  • [39] Invasive group B streptococcal infections in Finland, 1995-2000
    Lyytikainen, O
    Nuorti, P
    Halmesmäki, E
    Carlson, P
    Uotila, J
    Vuento, R
    Ranta, T
    Sarkkinen, H
    Ämmälä, L
    Kostiala-Thompson, A
    Järvenpää, AL
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1239 - 1239
  • [40] An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections
    Kotb, M
    Norrby-Teglund, A
    McGeer, A
    El-Sherbini, H
    Dorak, MT
    Khurshid, A
    Green, K
    Peeples, J
    Wade, J
    Thomson, G
    Schwartz, B
    Low, DE
    NATURE MEDICINE, 2002, 8 (12) : 1398 - 1404